Companies › Qlaris Bio
1 active drug program in 1 registered trial: 1 Phase 2; Ophthalmology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| QLS-111 Ophthalmic Solution | – | Phase 2 | Non-proliferative Diabetic Retinopathy (NPDR) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07354477 | QLS-111 Ophthalmic Solution | Phase 2 | Non-proliferative Diabetic Retinopathy (NPDR) | Ophthalmology | Oct 2026 |
No annotated target.
–
Aperta Biosciences Jiangsu Jingze Biopharmaceutical ONL Therapeutics BioTheraVision Vantage Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.